WO2011110225A1 - Timbre adhésif pour l'administration d'un agent thérapeutique - Google Patents

Timbre adhésif pour l'administration d'un agent thérapeutique Download PDF

Info

Publication number
WO2011110225A1
WO2011110225A1 PCT/EP2010/053096 EP2010053096W WO2011110225A1 WO 2011110225 A1 WO2011110225 A1 WO 2011110225A1 EP 2010053096 W EP2010053096 W EP 2010053096W WO 2011110225 A1 WO2011110225 A1 WO 2011110225A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesive patch
therapeutic agent
patch according
treatment
soluble film
Prior art date
Application number
PCT/EP2010/053096
Other languages
English (en)
Inventor
Robin List
Original Assignee
Sylphar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylphar filed Critical Sylphar
Priority to PCT/EP2010/053096 priority Critical patent/WO2011110225A1/fr
Priority to EP10707914A priority patent/EP2544669A1/fr
Publication of WO2011110225A1 publication Critical patent/WO2011110225A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to an adhesive patch for the delivery of at least one therapeutic agent.
  • Such adhesive patches are already known, for instance, for the transdermal delivery of therapeutic agents. However, they are relatively uncomfortable, usually do not offer a significant physical barrier, and require to be removed after use, which, for instance, may easily lead to re-infection.
  • the present invention solves these problems in that it comprises a soluble film incorporating said at least one therapeutic agent.
  • a soluble film provides a fast, accurate dosing that can be expected to increase compliance. There is no need for water or measuring, and upon dissolution of the film, an accurate dose of the at least one therapeutic agent is absorbed.
  • Today's consumers cite better portability, ease and accuracy of dosing, and overall convenience as the product attributes they seek most in medicine.
  • said adhesive patch is an adhesive patch for buccal or sublingual application for the treatment of mouth ulcers.
  • Aphthous stomatitis is an illness that causes small ulcers or "canker sores" to appear in the mouth, usually inside the lips, on the cheeks, or on the tongue.
  • canker sores may be caused by a faulty immune system that uses the body's defence against disease to attack and destroy the normal cells of the mouth or tongue.
  • aphthous stomatitis is one of the two major oral health problems around the world
  • said soluble film may comprise carbomer and/or polyethylene dioxide. These ensure a good adhesion of the film to the buccal mucosa, and a controlled dissolution of the film in the buccal environment.
  • said at least one therapeutic agent may comprise hyaluronic acid, red mangrove, and/or polyvinylpyrolidone.
  • Hyaluronic acid initiates the production of new cells and is responsible for initiating the healing process after trauma. Not only does it reduce the pain of canker sores but it also accelerates the healing of injured tissues in the mouth. Besides the inflammation, hyaluronic acid can reduce the healing time for the repair of damaged tissue by up to 50%. Red mangrove (Rhizophora mangle), and in particular its aqueous bark extract (RMABE), also reduces the time to repair mucosal tissue, erythema, ardour and pain persistence.
  • Red mangrove Rhizophora mangle
  • RMABE aqueous bark extract
  • Polyvinylpyrolidone has an ability to form complexes with a large number of substances, which can be used to reduce the toxicity of certain therapeutic agents. Moreover, it has a strong adhesive and binding power, which in this case ensures the adhesion of the patch to the buccal mucosa and forms a protective physical film covering the ulcerated area and isolating any infected tissue.
  • the adhesive patch may also further comprise an insoluble ingestible backing over said soluble film, the facilitate handling and placing the adhesive patch over the mouth sore. Since this backing is ingestible, it may be swallowed, even inadvertently, by the patient, after the soluble film dissolves entirely.
  • said insoluble ingestible layer may comprise ethylcellulose. Ethylcellulose is also a barrier forming agent: it forms a thin barrier over the exposed nerve endings on the mucosa, bringing pain relief.
  • the present invention also relates to a method of producing an adhesive patch comprising a soluble film incorporating said at least one therapeutic agent for buccal or sublingual application for the treatment of mouth ulcers, wherein said soluble film may contain carbomer and/or polyethylene dioxide, and said at least one therapeutic agent may comprise hyaluronic acid, red mangrove, polyvinylpyrolidone and/or cellulose.
  • said adhesive patch is an adhesive patch for labial application for the treatment of labial herpes.
  • the herpes simplex virus (HSV) causing herpes labialis cold sores is highly prevalent, and those cold sores unpleasant and embarrassing to the patients.
  • HSV herpes simplex virus
  • the use of this adhesive patch for the treatment of herpes labialis presents the advantages of ease of application, reducing the risk of cross-contamination when applying or removing the patch, since it can be simply washed away, and ensuring a long contact time of the at least one therapeutic agent.
  • the patch will create a protective barrier, thus ensuring pathogenic isolation of the cold sores caused by the viral infection.
  • said soluble film may comprise polyvinyl alcohol (PVA) and/or hydroxypropyl methyl cellulose (HPMC). Both kinds of soluble films present physical properties that facilitate their handling and their use in the present application.
  • PVA polyvinyl alcohol
  • HPMC hydroxypropyl methyl cellulose
  • said at least one therapeutic agent may comprise a zinc salt, preferably zinc sulphate; an immunomodulator, more preferably a glucan, in particular ⁇ -1 ,3-D-glucan; and/or at least one sulphated polysaccharide, preferably from an algal extract.
  • a zinc salt preferably zinc sulphate
  • an immunomodulator more preferably a glucan, in particular ⁇ -1 ,3-D-glucan
  • at least one sulphated polysaccharide preferably from an algal extract.
  • a topical zinc solution such as that formed by dissolving a zinc salt like zinc sulphate, has been shown to reduce both the number of episodes and the time to recovery of herpes labialis, as well as irreversibly inhibit HSV replication in vitro. Moreover, it has a preventive effect, against relapse of both herpes labialis and post-herpetic erythema multiforme. It improves wound healing, and stops pain, tingling and burning.
  • An immunomodulator such as ⁇ -1 ,3-D-glucan modulates wound healing via an indirect mechanism in which macrophages are stimulated to release growth factors and cytokines, enhancing immune system function and preventing subsequent infection.
  • Sulphated polysaccharides such as those from algal extracts, present anti-inflammatory, UV-protective and antiviral properties.
  • the adhesive patch may be pigmented, so as to help conceal unsightly cold sores.
  • the present invention also relates to a method of producing an adhesive patch comprising a soluble film incorporating said at least one therapeutic agent for labial application for the treatment of labial herpes, said at least one therapeutic agent may comprise a zinc salt, preferably zinc sulphate; an immunomodulator, preferably a glucan, in particular ⁇ -1 ,3-D-glucan; and at least one sulphated polysaccharide, preferably from an algal extract.
  • a zinc salt preferably zinc sulphate
  • an immunomodulator preferably a glucan, in particular ⁇ -1 ,3-D-glucan
  • at least one sulphated polysaccharide preferably from an algal extract.
  • the adhesive patch is an adhesive patch for dermal application for the treatment of skin wounds and/or ulcers.
  • the adhesive patch is a patch for buccal or sublingual application for the treatment of mouth ulcers.
  • An aphthous ulcer is a clearly defined painful, round or ovoid, shallow ulcer inside the oral cavity mainly in the mouth or upper throat and caused by a break in the mucous membrane.
  • the term aphthea means ulcers; it has been used for many years to describe areas of ulceration on mucous membranes.
  • Aphthous ulceration is a condition which is characterized by recurrent discrete areas of ulceration with chronic inflammatory properties and therefore sometimes referred as recurrent aphthous ulceration (RAU).
  • Recurrent aphthous ulceration can be distinguished from other oral diseases with similar-appearing oral lesions by their tendency to recur and their multiplicity.
  • Aphthous ulcers are classified according to the diameter of the lesion into minor, major and/or Herpetiform aphthea. Each of them associated with specific clinical features, (see table 1 ).
  • the overall view of its pathogenesis is a pluralistic or multifactorial one, that includes inducing and/or precipitating factors and triggers.
  • the primary disorder appears to be the result of activation of the cell- mediated immune system.
  • Cell-mediated immunity is an immune response that does not involve antibodies but rather involves the activation of other immune systems like macrophages and cytotoxic T- lymphocytes.
  • RAU Some precipitating factors of RAU include:
  • Trauma Local injury, such as that caused by an accidental bite, toothbrush bristle, ...may precipitate aphthous ulcers in individuals who are susceptible.
  • ulcerative colitis may result in aphthous ulcers.
  • the ulcers may be the only presenting symptom or the only symptom that is evident for a number of years in patients with Gl disorders.
  • - Systemic disorders Disorders such as Behget disease, or HIV infection may result in aphthous ulcers.
  • Flavoring agents essential oils, benzoic acid, cinnamon, gluten, cow's milk, coffee, chocolate, potatoes, cheese, figs, nuts, citrus fruits, and certain spices have been implicated in some individuals with RAUs.
  • RAUs are associated with the menstrual cycle, with outbreaks most commonly occurring during ovulation or before menstruation.
  • Chemical exposures High levels of nitrates in drinking water have been associated withaphthous ulcers.
  • Sodium lauryl sulfate (SLS) a detergent commonly used in toothpaste, may be a trigger of aphthous ulceration in some individuals.
  • the goal of RAU treatment is to provide the patient with control over this condition by increasing comfort, decreasing the frequency of future ulceration, and promoting healing of existing ulcers.
  • the main over-the-counter preparations consist of topical gels, creams, pastes and/or liquids containing topical anesthetics.
  • those devices Beside the limited therapeutic action, those devices are focused on pain treatment and not on promoting healing of existing ulcerated areas.
  • prescription medication is additionally advised by the clinician such as tetracycline, acyclovir, colchicine and prednisone suspensions.
  • anxiolytic agents or antidepressants are prescribed because they may be helpful for some patients if RAU are precipitated by stress.
  • the delivery device that the adhesive patch of this first embodiment uses is a thin, soluble, mucoadhesive film.
  • a thin, soluble, mucoadhesive film provides fast, accurate dosing and increased patient compliance.
  • This thin, soluble, mucoadhesive film is loaded with active ingredients. Those therapeutic agents will be released slowly and in a sustained manner onto the infected area. This will heal and decrease pain instantly but also in time.
  • the delivery device being a film that sticks to the infected area, a treatment therapy is possible, since the wash away and dilution effect of the saliva is avoided.
  • the therapeutic agents are targeted onto the infected area by the mucoadhesive film and are not diluted. This lies in strong contrast with the classic delivery devices (creams, gels, pastes and liquids) that are currently used.
  • the contact time between the ulcerated surface and the active ingredients is maximized. This leads to a single-application treatment and therefore contributes to the therapy compliance.
  • the physical properties of the film will create a strong barrier between the ulcerated area and the oral cavity. This will isolate the aphthous ulceration and will prevent painful stimuli (e.g. cold drinks, tongue, food,...) to reach the infected tissues.
  • the adhesive patch is a disc with 12 mm of diameter that can adhere to the mucosal lining of the cheek for up to 40 minutes.
  • the active therapeutic agents in the thin, soluble, mucoadhesive film are hyaluronic acid, in a concentration of 4.2 % wt. of the film, and red mangrove aqueous bark extract, in a concentration of 33.5 % wt. of the film.
  • Hyaluronic acid is a naturally occurring polysaccharide, a glycosaminoglycan, that consists of N-acetyl-diglucosamine and beta- glucoronic acid.
  • HA is a vital substance produced by the body which initiates the production of new cells as part of the wear and tear process and is responsible for initiating the healing process after trauma. Therefore HA is present in the intercellular matrix of most connective tissues, especially skin where it has a protective, structure stabilizing and shock-absorbing role. Many of the biological processes mediated by HA are central to the wound healing process. Following injury, wound healing relies on a series of tightly regulated sequential events, e.g. inflammation, formation of granulation tissue, reepithelization, and remodeling.
  • HA has been found to be particularly suited to reform gingival tissues and to regulate the healing of the gums to a normal physiological state.
  • Hyaluronic acid is also an indispensable component of intact, healthy gums and oral mucosal tissue. It is distributed in a selective, specific manner and it tends to concentrate particularly in those layers of the gingival epithelium closest to the surface where it acts as a barrier imparting stability and elasticity to the tissue.
  • HA One of the main actions of HA is that of normalizing the natural structure of the connective tissue, accelerating the rate of tissue reconstruction. HA regulates also the cell permeability and reduces the abnormally high capillary permeability. This helps to prevent infestation by nfectious micro-organisms, thus inhibiting the destruction of tissue.
  • Hyaluronic acid in tissue regeneration is its ability to influence the migration of fibroblasts (a cell that synthesizes and maintains the tissue matrix) with the result that scar tissue formation and wound healing are promoted. It has been shown by A. Nolan et al. in "The efficiency of topical hyaluronic acid in the management of RAU", JOPM (2006) 35: 461 -5, that HA not only reduces the pain of aphthous ulcerations but also accelerates the healing of injured tissues in the mouth.
  • HA possesses an extremely high capacity to bind water (up to 50 times its own volume). Thanks to this property, HA possesses an anti-oedematous effect.
  • HA is also able to bind specific proteins and tissue polysaccharides and thus form a viscous macro-aggregate which will protect the injured area .
  • HA Another action of HA is the inactivation of the hyaluronidase enzyme of certain malign bacteria, which results in an anti-inflammatory effect. It has been confirmed by Innocenti et al., in "Efficacy of topical hyaluronic acid in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study, J Pain Symptom Manage, 24(5): 546-7, 2002, that HA has the ability to reduce inflammation and the healing time for the repair of damaged tissue by up to 50%. HA has also been found by Voinchet et al., in “Efficacy and safety of hyaluronic acid in the management of acute wounds", Am J Clin Dermatol. 2006;7(6):353-7, to be well tolerated and show no adverse events.
  • Rhizophora mangle (Rhizophoraceae), the red mangrove, is a subtropical/tropical tree which colonizes coastlines and brackish water habitats below the 20 °C isotherm in both the northern and southern hemispheres. It is widely distributed along the tropical and subtropical coasts of America from Bermuda to Florida, Occidental Africa and the islands of Fiji, Tonga and New Caledonia and is a characteristic tree of the lower and swampy zones of the Cuban archipelago. According to Roig et al., "Plantas medicinales, aromaticas y venenosas de Cuba", 1974 Editorial Revolucion y Progressiveo, La Habana, p. 745, Rhizophora mangle has been used in traditional medicine as astringent, antiseptic and haemostatic with antifungic and antiulcerogenic properties.
  • Rhizophoria mangle Exemption From the Requirement of a Tolerance
  • Federal Register May 7, 1997 (Volume 62, Number 88)
  • the Agency has determined that all toxicology data requirements have been satisfied and that no harm will result from aggregate exposure, including infants and children, to residues of plant extract from Rhizophoria mangle (mangrove).
  • the ethylcellulose of the backing layer also has a therapeutic activity, as it is also a barrier forming agent: it forms a thin barrier over the exposed nerve endings on the mucosa, bringing pain relief. All these three kinds of therapeutic agents have been found to be particularly adapted for their delivery through a soluble film. In combination, they have turned out to be particularly effective.
  • therapeutic agents such as polyvinylpyrolidone (PVP), could also be considered by the skilled person, preferably in the soluble film, but also in the backing layer.
  • PVP polyvinylpyrolidone
  • PVP for instance, is a very well known ingredient in the pharmaceutical industry and it has several applications in pharmaceuticals (see table 2).
  • PVP protein styrene-maleic anhydride copolymer
  • PVP can be used to reduce the toxicity of certain active ingredients.
  • PVP is also being used as a reducer of irritant or toxic effects of other substances, as shown in Wilkinson et al., CSMA Proceedings, 40th Midyear Meeting of the Chem. Spec. Manufacturers Ass. Inc. (1953).
  • PVP is also used as adhesives on the skin or mucous membranes.
  • PVP has been used, according to Vyas et al., Uppadbayay, Drug Dev. Ind. Pharm. 20 No. 1 , 101-1 10 (1994), as an adhesive, to improve or control transdermal absorption, or to stabilize active substances.
  • PVP has been cited by Perioli et al., in "Development of mucoadhesive patches for buccal administration of ibuprofen", Journal of Controlled Release Volume 99, Issue 1 , 14 September 2004, Pages 73-8, as one of the best film forming agents 20.
  • PVP may be used in the adhesive patch of the present invention mainly for its film forming action.
  • the abovementioned mucoadhesive film of forms a physical film barrier that covers the ulcerated area and therefore substantially isolates the infected tissues.
  • the adhesive patch may also comprise additional ingredients, such as colorants (for instance Allura Red [E129] and Titanium dioxide [E171 ] for the pink and red-brown colors), flavors (for instance mint flavor), sweeteners (for instance Acesulfame K [E950] and Sucralose [E955]), and lubricants/plasticizers such as dibutylsebicate.
  • colorants for instance Allura Red [E129] and Titanium dioxide [E171 ] for the pink and red-brown colors
  • flavors for instance mint flavor
  • sweeteners for instance Acesulfame K [E950] and Sucralose [E955]
  • lubricants/plasticizers such as dibutylsebicate.
  • the patient can himself hold the adhesive patch by the pink-colored backing layer, moisten the red-brown-colored adhesive film, and stick the patch onto the mouth ulcer, where it will cover the ulcer and gradually release its at least one therapeutic agent.
  • the backing layer will be ingested by the patient, usually inadvertently.
  • the present invention is alternatively embodied in an adhesive patch for labial application for the treatment of labial herpes.
  • Previous OTC systems for the delivery of therapeutic agents for the treatment of labial "cold sores" caused by HSV infection are limited to gels and tablets. These delivery systems present side effects and lack effectiveness. Being usually based on acyclovir/penciclovir, they present a narrow treatment spectrum. Moreover, in the labial environment, these previous delivery systems only offer a short contact time for the effective delivery of the therapeutic agent, a particularly critical drawback considering that the timing of the treatment is crucial for its effectiveness. Frequent readministration using these previous OTC delivery systems only increases the risk of cross-contamination. While patches for concealing cold sores have been proposed under the "Compeed®" trademark, these do not comprise any therapeutic agent. Moreover, they require to be frequently removed and replaced by hand, greatly increasing the risk of cross-contamination.
  • the soluble film may be chosen, for instance, from among those currently sold by Watson, Inc. under the designations QSA 2000 (a fast dissolving hot and cold water soluble film based on polyvinyl alcohol) or EM 1 100 (a food grade, edible, heat sealable, cold water soluble film based on hydroxypropyl methyl cellulose).
  • QSA 2000 a fast dissolving hot and cold water soluble film based on polyvinyl alcohol
  • EM 1 100 a food grade, edible, heat sealable, cold water soluble film based on hydroxypropyl methyl cellulose.
  • Such soluble films offer the advantages of being breathable, yet forming a physical protective barrier over the cold sore, and gradually delivering the therapeutic agent or agents directly onto the infected area. Moreover, they can be directly washed off after use, thus very substantially reducing the risk of cross-contamination.
  • the agents incorporated into the soluble film comprise zinc sulphate, ⁇ - 1 ,3-D-glucan as an immunomodulator, and an algal extract and comprising a sulphated polysaccharide.
  • zinc sulphate ⁇ - 1 ,3-D-glucan as an immunomodulator
  • algal extract and comprising a sulphated polysaccharide.
  • alternative combinations of these and related therapeutic agents could also be considered by the skilled person.
  • Topical zinc solutions have been shown, for instance by Park et al, "Topical Zinc Sulphate Therapy in Herpex Simplex", Korean J Dermatol 26(4): 529-535, to be an effective agent for the treatment and prevention of recurrence of HSV infection.
  • Famiano et al "Recurrent herpes labial is: a pilot study of the efficacy of zinc therapy", Oral Pathol Med (2005) 34: 423-5, systemic zinc sulphate appeared to reduce both the number of episodes and the time to recovery of herpes labialis.
  • Topical zinc has been shown to improve wound healing by Agren MS in “Studies on zinc in wound healing", Acta Derm Venereol (Suppl), 1990; 154:1 -36, and topical zinc has also been shown to have an acute therapeutic effect on HSV infections by Eby GA and Halcomb WW in "Use of topical zinc to prevent recurrent herpes simplex infection: Review of literature and suggested protocols", Med Hypotheses, 1985; 17:157, by Wahba A et al in “Topical application of zinc solutions: a new treatment for herpes simplex infections of the skin", Acta Derm Venereol.
  • ⁇ -1 ,3-D-glucan is an immunomodulator which has been shown to modulate wound healing, for instance by Duo Wei et al in "Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism", Wound Repair and Regeneration, vol. 10, 3, pp 161 -168. It has been shown to enhance immune system reaction, see for instance Keller et al, "Compounding with -1 ,3-D-glucan", International Journal of Pharmaceutical Compounding, vol. 4, No.
  • Sulphated polysaccharides obtained from red algae were proposed as an effective anti-inflammatory for topical use by Matsui et al in "Sulfated Polysaccharides from Red Microalgae Have Antiinflammatory Properties In Vitro and In Vivo", Applied Biochemistry and Biotechnology, Vol. 104, 2003. They also have a positive effect as UV-protectors, according to Wu H-K et al, "Aging and wrinkle formation of skin caused by UV exposure are prevented and cured by the treatment of alga- extractive product", Fragr J, vol. 29, no. 3, pp. 56-61 (2001 ).
  • the adhesive patch may be an adhesive patch for dermal application for the treatment of skin wounds and/or ulcers.
  • the soluble films and/or therapeutic agents in this embodiment may for example be chosen from among any of the soluble films and therapeutic agents of the previous embodiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Timbre adhésif pour l'administration d'au moins un agent thérapeutique, ledit timbre comprenant un film soluble imprégné dudit au moins agent thérapeutique.
PCT/EP2010/053096 2010-03-11 2010-03-11 Timbre adhésif pour l'administration d'un agent thérapeutique WO2011110225A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/053096 WO2011110225A1 (fr) 2010-03-11 2010-03-11 Timbre adhésif pour l'administration d'un agent thérapeutique
EP10707914A EP2544669A1 (fr) 2010-03-11 2010-03-11 Timbre adhésif pour l'administration d'un agent thérapeutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/053096 WO2011110225A1 (fr) 2010-03-11 2010-03-11 Timbre adhésif pour l'administration d'un agent thérapeutique

Publications (1)

Publication Number Publication Date
WO2011110225A1 true WO2011110225A1 (fr) 2011-09-15

Family

ID=43085887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/053096 WO2011110225A1 (fr) 2010-03-11 2010-03-11 Timbre adhésif pour l'administration d'un agent thérapeutique

Country Status (2)

Country Link
EP (1) EP2544669A1 (fr)
WO (1) WO2011110225A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915568A1 (fr) * 2020-05-29 2021-12-01 Piccolo Federico Composition mucoadhésive à utiliser dans le traitement des plaies buccales

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120768A1 (fr) * 2006-04-13 2007-10-25 Haley Jeffrey T Timbre administré par voie orale comprenant un sel d'acide glycyrrhétinique soluble dans l'eau à une température correspondant à celle de la bouche d'un être humain
WO2007149902A1 (fr) * 2006-06-20 2007-12-27 Izun Pharmaceuticals Corporation Film anti-inflammatoire soluble
EP2151252A2 (fr) * 2008-08-04 2010-02-10 BIOFARMITALIA S.p.A. Film solide, rapidement soluble dans des liquides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120768A1 (fr) * 2006-04-13 2007-10-25 Haley Jeffrey T Timbre administré par voie orale comprenant un sel d'acide glycyrrhétinique soluble dans l'eau à une température correspondant à celle de la bouche d'un être humain
WO2007149902A1 (fr) * 2006-06-20 2007-12-27 Izun Pharmaceuticals Corporation Film anti-inflammatoire soluble
EP2151252A2 (fr) * 2008-08-04 2010-02-10 BIOFARMITALIA S.p.A. Film solide, rapidement soluble dans des liquides

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
A. NOLAN ET AL.: "The efficiency of topical hyaluronic acid in the management of RAU", JOPM, vol. 35, 2006, pages 461 - 5
ANONYMUS: "Gelclair Bioadherent oral gel", INTERNET CITATION, October 2006 (2006-10-01), pages 1 - 2, XP002605344, Retrieved from the Internet <URL:http://www.gelclair.com/pi.htm> [retrieved on 20101015] *
BRODY ET AL.: "Topical treatment of recurrent herpes simplex and post-herpetic erythema multiforme with low concentrations of zinc sulphate solution", BRITISH JOURNAL OF DERMATOLOGY, vol. 104, no. 2, pages 191 - 194
COMMUNITY DENT ORAL EPIDEMIOL., vol. 22, no. 4, August 1994 (1994-08-01), pages 243 - 53
DE ARMAS ELIZABETH ET AL: "Efficacy of Rhizophora mangle aqueous bark extract (RMABE) in the treatment of aphthous ulcers: a pilot study", CURRENT MEDICAL RESEARCH AND OPINION, INFORMA HEALTHCARE, GB, vol. 21, no. 11, 1 November 2005 (2005-11-01), pages 1711 - 1715, XP008128013, ISSN: 0300-7995 *
DUO WEI ET AL.: "Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism", WOUND REPAIR AND REGENERATION, vol. 10, no. 3, pages 161 - 168
EBY GA; HALCOMB WW: "Use of topical zinc to prevent recurrent herpes simplex infection: Review of literature and suggested protocols", MED HYPOTHESES, vol. 17, 1985, pages 157
FAMIANO ET AL.: "Recurrent herpes labialis: a pilot study of the efficacy of zinc therapy", ORAL PATHOL MED, vol. 34, 2005, pages 423 - 5
FINNERTY EF: "Topical zinc in the treatment of herpex simplex", CUTIS, vol. 37, 1986, pages 130 - 131
GODFREY ET AL.: "A randomized clinical trial on the treatment of oral herpes with topical ZnO/glycine", ALTERNATIVE THERAPIES, vol. 7, no. 3, May 2001 (2001-05-01)
GREN MS: "Studies on zinc in wound healing", ACTA DERM VENEREOL, vol. 154, 1990, pages 1 - 36
INNOCENTI ET AL.: "Efficacy of topical hyaluronic acid in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study", J PAIN SYMPTOM MANAGE, vol. 24, no. 5, 2002, pages 546 - 7
KELLER ET AL.: "Compounding with f3-1,3-D-g!ucan", INTERNATIONAL JOURNAL OF PHARMACEUTICAL COMPOUNDING, vol. 4, no. 5, September 2000 (2000-09-01)
KOVAC; KAVCIC, JOURNAL OF ORAL PATHOLOGY AND MEDICINE, vol. 29, 2000, pages 331
MARCO AVERBECK ET AL.: "Differential Regulation of Hyaluronan Metabolism in the Epidermal and Dermal Compartments of Human Skin by UVB Irradiation", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, 2007, pages 687 - 697
MATSUI ET AL.: "Sulfated Polysaccharides from Red Microalgae Have Antiinflammatory Properties In Vitro and In Vivo", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 104, 2003
MELCHOR ET AL.: "Antibacterial activity of Rhizophora mangle bark", vol. 72, 2001, FITOTERAPIA, pages: 689 - 691
MORTON ET AL.: "Atlas of medicinal plants of Middle America", 1981, BAHAMAS TO YUCATAN
PARK ET AL.: "Topical Zinc Sulphate Therapy in Herpex Simplex", KOREAN J DERMATOL, vol. 26, no. 4, pages 529 - 535
PERIOLI ET AL.: "Development of mucoadhesive patches for buccal administration of ibuprofen", JOURNAL OF CONTROLLED RELEASE, vol. 99, no. 1, 14 September 2004 (2004-09-14), pages 73 - 8
ROBINSON ET AL.: "PVP - A Critical Review of the Kinetics and Toxicology of Polyvinylpyrrolidone (Povidone)", 1990, LEWIS PUBLISHERS
ROIG ET AL.: "Plantas medicinales, aromaticas y venenosas de Cuba", 1974, LA HABANA, pages: 745
SHI C ET AL: "Phenolic compounds and their anti-oxidative properties and protein kinase inhibition from the Chinese mangrove plant Laguncularia racemosa", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 71, no. 4, 1 March 2010 (2010-03-01), pages 435 - 442, XP026904361, ISSN: 0031-9422, [retrieved on 20091218], DOI: DOI:10.1016/J.PHYTOCHEM.2009.11.008 *
VOINCHET ET AL.: "Efficacy and safety of hyaluronic acid in the management of acute wounds", AM J CLIN DERMATOL., vol. 7, no. 6, 2006, pages 353 - 7
VYAS ET AL., UPPADBAYAY, DRUG DEV. IND. PHARM., vol. 20, no. 1, 1994, pages 101 - 110
WAHBA A ET AL.: "Topical application of zinc solutions: a new treatment for herpes simplex infections of the skin", ACTA DERM VENEREOL., vol. 60, no. 2, 1980, pages 175 - 77
WILKINSON ET AL.: "CSMA Proceedings, 40th Midyear Meeting of the Chem. Spec. Manufacturers Ass. Inc.", 1953
WILLIAMS JD; CZOP JK; AUSTEN KF: "Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators", J IMMUNOL, vol. 132, 1984, pages 3034 - 3040
WU H-K ET AL.: "Aging and wrinkle formation of skin caused by UV exposure are prevented and cured by the treatment of alga- extractive product", FRAGR J, vol. 29, no. 3, 2001, pages 56 - 61

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915568A1 (fr) * 2020-05-29 2021-12-01 Piccolo Federico Composition mucoadhésive à utiliser dans le traitement des plaies buccales

Also Published As

Publication number Publication date
EP2544669A1 (fr) 2013-01-16

Similar Documents

Publication Publication Date Title
US10966927B2 (en) Petrolatum-based delivery systems and for active ingredients
ES2278393T3 (es) Tratamiento antimicrobiano del virus herpes simplex y otras enfermedades infecciosas.
RU2571063C2 (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
Hamdy et al. Management of aphthous ulceration with topical quercetin: a randomized clinical trial
AU2008238445A1 (en) Extract of Trigonella foenum-graecum
AU2002312416A1 (en) Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
Buggapati Herbs in dentistry
JP2009530350A (ja) 口唇単純ヘルペス感染症の治療および／または予防のための局所使用用スプレー組成物
RU2562580C2 (ru) Полисахарид семян для применения в лечении воспалительных заболеваний
Burgess et al. Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract
Subiksha Various remedies for recurrent aphthous ulcer-a review
CA2783612A1 (fr) Composition destinee au traitement des lesions cutanees
Shemer et al. Efficacy of a mucoadhesive patch compared with an oral solution for treatment of aphthous stomatitis
BE1019216A3 (nl) Kleefpleister voor de toediening van therapeutische agentia.
RU2184538C2 (ru) Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт
VITALIEVICHAVERYANOV et al. Efficiency of clinical application of phytofilm in treating patients with traumatic lesions of oral mucosa
CN102552734B (zh) 一种治疗口腔溃疡的漱口液
US11298393B2 (en) Composition comprising a mixture of an extract and bentonite
WO2011110225A1 (fr) Timbre adhésif pour l&#39;administration d&#39;un agent thérapeutique
CN117137869B (zh) 一种用于口腔粘膜保护及修复的凝胶喷雾剂、制备方法及其应用
RU2808191C1 (ru) Способ лечения хронического пародонтита
RU2675860C1 (ru) Способ местного лечения типичной формы красного плоского лишая слизистой оболочки рта с использованием адгезивных пластин, содержащих биогель ламифарэн
KR20180030482A (ko) 점막 병변 치료를 위한 제형
US20110229584A1 (en) Compound for the control of herpes simplex virus using glycyrrhizic acid, lipoic acid, allantoin, and slippery elm
Curt-Mola et al. Comparative Effectiveness of Alternative Medication in Minor Aphtous Stomatitis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707914

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010707914

Country of ref document: EP